ACRX - AcelRx Pharmaceuticals GAAP EPS of $1.00 beats by $1.51 revenue of $0.25M misses by $4.25M
2023-03-30 16:11:21 ET
- AcelRx Pharmaceuticals press release ( NASDAQ: ACRX ): Q4 GAAP EPS of $1.00 beats by $1.51 .
- Revenue of $0.25M (+1150.0% Y/Y) misses by $4.25M .
- Divestment of DSUVIA to Alora Pharmaceuticals expected to close the week of April 3, 2023
For further details see:
AcelRx Pharmaceuticals GAAP EPS of $1.00 beats by $1.51, revenue of $0.25M misses by $4.25M